Symptomatic diabetic autonomic neuropathy in type 1 diabetes (T1D): Findings from the T1D exchange

J Diabetes Complications. 2022 May;36(5):108148. doi: 10.1016/j.jdiacomp.2022.108148. Epub 2022 Feb 7.

Abstract

Aims: We aimed to evaluate the contemporary prevalence of and risk factors for symptomatic diabetic autonomic neuropathy (DAN) in participants with type 1 diabetes (T1D) enrolled in the T1D Exchange Clinic Registry.

Methods: DAN symptoms and severity were assessed with the Survey of Autonomic Symptoms (SAS) in adults with ≥5 years of T1D participating in the T1D Exchange from years 2010-2017. Associations of demographic, clinical, and laboratory factors with symptomatic DAN were assessed.

Results: Of the 4919 eligible T1D participants, 965 (20%) individuals completed the SAS questionnaire [mean age 40 ± 17 years, median diabetes duration 20 years (IQR: 13,34), 64% female, 90% non-Hispanic White, and 82% with private insurance]. DAN symptoms were present in 166 (17%) of responders with 72% experiencing moderate severity symptoms or worse. Symptomatic DAN participants had higher hemoglobin A1c (p = 0.03), longer duration (p = 0.004), were more likely to be female (p = 0.03), and more likely to have lower income (p = 0.03) versus no DAN symptoms. Symptomatic DAN was associated with diabetic peripheral neuropathy (p < 0.0001), smoking (p = 0.002), cardiovascular disease (p = 0.02), depression (p < 0.001), and opioid use (p = 0.004).

Conclusions: DAN symptoms are common in T1D. Socioeconomic factors and psychological comorbidities may contribute to DAN symptoms and should be explored further.

Keywords: Autonomic neuropathy; Cardiovascular autonomic neuropathy; Type 1 diabetes; Type 1 diabetes exchange registry.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Autonomic Nervous System Diseases* / complications
  • Autonomic Nervous System Diseases* / epidemiology
  • Cardiovascular Diseases* / epidemiology
  • Diabetes Mellitus, Type 1* / complications
  • Diabetes Mellitus, Type 1* / epidemiology
  • Diabetic Neuropathies* / complications
  • Diabetic Neuropathies* / diagnosis
  • Diabetic Neuropathies* / epidemiology
  • Female
  • Glycated Hemoglobin / analysis
  • Humans
  • Male
  • Middle Aged
  • Risk Factors
  • Young Adult

Substances

  • Glycated Hemoglobin A